|By PR Newswire||
|April 28, 2014 04:00 AM EDT||
OXFORD, England, April 28, 2014 /PRNewswire-USNewswire/ -- Orca Pharmaceuticals, a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases, has announced a further investment of $1.3 million from BioMotiv, a drug development accelerator based in Cleveland, Ohio and affiliated with The Harrington Project. Founded in 2013, the company's technology is based on intellectual property developed in the laboratory of Professor Dan Littman of New York University, a world leader in Th17 cell immunology. Orca also has close ties with Oxford University immunologists who are playing a key role in identifying promising therapeutic indications and selecting an optimised development candidate.
"This additional funding endorses the strength of the Orca program and provides resources for the advancement of a development candidate," said Roy Pettipher, PhD, founder and Chief Scientific Officer of Orca Pharmaceuticals.
Orca Pharmaceuticals is developing an oral drug to treat a range of autoimmune diseases, with psoriasis as the primary therapeutic target. Working with Evotec AG, the company has developed a series of potent and selective compounds with pharmaceutical properties that are amenable to clinical development. The additional investment will enable the company to select a clinical candidate optimised for activity on key pathogenic immune cells.
"The powerful combination of high quality medicinal chemistry, target structure analysis, and leading edge biological screening has enabled Orca to obtain potentially best-in-class RORgamma inhibitors targeting a variety of immune diseases," said David C. U'Prichard, PhD, Board Chairman of Orca Pharmaceuticals, and Chief Scientific Officer of BioMotiv.
Mick Hunter, PhD, CEO of Orca Pharmaceuticals, indicated that the company is now exploring additional development partnerships with pharmaceutical companies.
Orca Pharmaceuticals Ltd
+44 (0) 1235 841542
About Orca Pharmaceuticals
Orca Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization via partnership of targeted small molecule RORgamma inhibitor drugs to treat patients with autoimmune disease. For more information, please visit: http://www.orcapharmaceuticals.com
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative for advancing medicine centered at University Hospitals of Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs. Products are advanced to clinical proof-of-concept and then partnered. BioMotiv is interested in early-stage therapeutics in all disease areas. Learn more at www.biomotiv.com.
SOURCE Orca Pharmaceuticals
Oct. 9, 2015 11:15 PM EDT Reads: 197
Oct. 9, 2015 11:00 PM EDT Reads: 636
Oct. 9, 2015 10:15 PM EDT Reads: 210
Oct. 9, 2015 10:15 PM EDT Reads: 136
Oct. 9, 2015 10:00 PM EDT Reads: 243
Oct. 9, 2015 10:00 PM EDT Reads: 452
Oct. 9, 2015 10:00 PM EDT Reads: 196
Oct. 9, 2015 09:30 PM EDT Reads: 311
Oct. 9, 2015 09:00 PM EDT Reads: 416
Oct. 9, 2015 08:00 PM EDT Reads: 935
Oct. 9, 2015 08:00 PM EDT Reads: 316
Oct. 9, 2015 07:45 PM EDT Reads: 171
Oct. 9, 2015 06:45 PM EDT Reads: 230
Electric power utilities face relentless pressure on their financial performance, and reducing distribution grid losses is one of the last untapped opportunities to meet their business goals. Combining IoT-enabled sensors and cloud-based data analytics, utilities now are able to find, quantify and reduce losses faster – and with a smaller IT footprint. Solutions exist using Internet-enabled sensors deployed temporarily at strategic locations within the distribution grid to measure actual line lo...
Oct. 9, 2015 06:30 PM EDT Reads: 140
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Oct. 9, 2015 06:00 PM EDT Reads: 324